Sarah Walbolt/LinkedIn
Aug 20, 2026, 13:15
Sarah Walbolt: Study Findings Challenge Long-Term Anticoagulation
Sarah Walbolt, Program Manager at University of Utah Health, Chief Executive Officer Sanguine Health Holdings Inc, shared a post LinkedIn about a recent article by Sabine Eichinger et al., published in Blood Advances, adding:
”Terminated study due to risk: Findings challenge current treatment paradigms and support individualized decisions regarding anticoagulation duration.
Would love your thoughts!”
Title: Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study
Authors: Sabine Eichinger, Lisbeth Eischer, Alexandra Kaider, Georg Heinze, Peter Quehenberger, Paul A. Kyrle
Stay updated on the latest scientific advances with Hemostasis Today.
-
Aug 20, 2026, 14:08Ahmed Mostafa: Decoding HLA-B27 in Ankylosing Spondylitis
-
Aug 20, 2026, 14:02Rafail A. Kotronias: Improving the Detection and Management of Coronary Microvascular Obstruction
-
Aug 20, 2026, 14:00Cindy Neunert: What Matters Most to Patients with ITP
-
Aug 20, 2026, 13:46Mario Enrico Canonico։ CLEAR Outcomes Analysis Highlights Bempedoic Acid Benefits in PAD
-
Aug 20, 2026, 13:34Ons Marsit: What Is the Residual Thromboembolic Risk After AF Ablation?
-
Aug 20, 2026, 13:21Lacy Almeida: How to Safely Prescribe Antidepressants With Bleeding-Risk Medications?
-
Aug 20, 2026, 13:04Matteo Foschi: New Insights Into Breakthrough Ischemic Stroke
-
Aug 20, 2026, 12:22Agnese Lucchetti: High Shear Drives Acute Carotid Stent Thrombosis in Tandem Lesions
-
Aug 20, 2026, 11:12Ayatullah Gamal Wahab: When The Platelet Count Lies